SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002165
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002165/ea020832402ex1-1_synergy.htm

Chunk 1 of 15
Word Count: 1400
Character Count: 9033

Document Content:

times though the completion of the public offer and sale of Shares, has, does or will include (1) any untrue statement of a material fact or omission to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (2) information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Final Prospectus. The representations and warranties set forth in the immediately preceding sentence shall not apply to statements in or omissions from the Time of Sale Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company by any Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f). As used in this paragraph and elsewhere in this Agreement:

“Time of Sale Disclosure Package” means the Prospectus most recently filed with the Commission before the time
of this Agreement each Issuer Free Writing Prospectus, and the description of the transaction provided by the Underwriters included
on Schedule II.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 under
the Securities Act, relating to the Shares that (A) is required to be filed with the Commission by the Company, or (B) is exempt from
filing pursuant to Rule 433(d)(5)(i) or (d)(8) under the Securities Act, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the
Securities Act.

At the time of filing of the Registration Statement and at the date hereof, the Company was not and is not an “ineligible issuer,”
as defined in Rule 405 under the Securities Act or an “excluded issuer” as defined in Rule 164 under the Securities Act.

Each Issuer Free Writing Prospectus listed on Schedule III satisfied, as of its issue date and at all subsequent times through
the Prospectus Delivery Period, all other conditions as may be applicable to its use as set forth in Rules 164 and 433 under the Securities
Act, including any legend, record-keeping or other requirements.

Financial Statements. The financial statements of the Company, together with the related notes and schedules, included in the
Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the
rules and regulations of the Commission thereunder, and fairly present the financial condition of the Company as of the dates indicated
and the results of operations and changes in cash flows for the periods therein specified in conformity with U.S. generally accepted
accounting principles (“GAAP”) consistently applied throughout the periods involved. No other financial statements
or schedules are required under the Securities Act, the Exchange Act, or the Rules and Regulations to be included in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus.

Independent Accountants. To the Company’s knowledge, RBSM LLP, which has expressed its opinion with respect to the financial
statements and schedules included as a part of the Registration Statement and included in the Registration Statement, the Time of Sale
Disclosure Package and the Final Prospectus, is an independent public accounting firm with respect to the Company within the meaning
of the Securities Act and the Rules and Regulations.

(vii)
Accounting and Disclosure Controls. Except as disclosed in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus, the Company and its subsidiaries maintain systems of “internal control
over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act) that comply with the requirements of
the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial
officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general
or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included
or incorporated by references in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus fairly present
the information called for in all material respects and are prepared in accordance with the Commission’s rules and guidelines applicable
thereto. Since the date of the latest audited financial statements included in the Registration Statement, the Time of Sale Disclosure
Package and the Final Prospectus, there has been no change in the Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Except
as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company maintains disclosure
controls and procedures that have been designed to ensure that material information relating to the Company and any subsidiaries is made
known to the Company’s principal executive officer and principal financial officer by others within those entities; and such disclosure
controls and procedures are effective.

(viii)
Forward-Looking Statements. The Company had a reasonable basis for, and made in good faith, each “forward-looking statement”
(within the meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained or incorporated by reference in
the Registration Statement, the Time of Sale Disclosure Package, the Final Prospectus or the Marketing Materials.

Statistical and Marketing-Related Data. All statistical or market-related data included or incorporated by reference in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived
from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the
use of such data from such sources, to the extent required.

Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on the
Nasdaq Capital Market (the “Nasdaq”). There is no action pending by the Company or, to the Company’s knowledge,
the Nasdaq to delist the Common Stock from the Nasdaq, nor has the Company received any notification that the Nasdaq is contemplating
terminating such listing. When issued, the Shares will be listed on the Nasdaq. The Company has taken all actions it deems reasonably
necessary or advisable to take on or prior to the date of this Agreement to assure that it will be in compliance in all material respects
with all applicable corporate governance requirements set forth in the rules of the Nasdaq that are then in effect and will take all
action it deems reasonably necessary or advisable to assure that it will be in compliance in all material respects with other applicable
corporate governance requirements set forth in the Nasdaq rules not currently in effect upon and all times after the effectiveness of
such requirements.

Absence of Manipulation. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted
or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Shares.

(xii)
Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Shares and the application
of the net proceeds thereof, will not be an “investment company,” as such term is defined in the Investment Company Act of
1940, as amended.

Representations and Warranties Regarding the Company.

The Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date and
as of each Option Closing Date, as follows: